541 related articles for article (PubMed ID: 21482566)
41. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.
Maselli DJ; Fernandez JF; Whong CY; Echevarria K; Nambiar AM; Anzueto A; Restrepo MI
Infect Drug Resist; 2012; 5():43-51. PubMed ID: 22355258
[TBL] [Abstract][Full Text] [Related]
42. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.
Riccobene T; Jakate A; Rank D
J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097
[TBL] [Abstract][Full Text] [Related]
43. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Jorgenson MR; DePestel DD; Carver PL
Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
[TBL] [Abstract][Full Text] [Related]
44. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
Zhanel GG; Sniezek G; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2009; 69(7):809-31. PubMed ID: 19441869
[TBL] [Abstract][Full Text] [Related]
45. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
Corey GR; Wilcox MH; Gonzalez J; Jandourek A; Wilson DJ; Friedland HD; Das S; Iaconis J; Dryden M
Int J Antimicrob Agents; 2019 Jun; 53(6):830-837. PubMed ID: 30716446
[TBL] [Abstract][Full Text] [Related]
46. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
File TM; Segreti J; Dunbar L; Player R; Kohler R; Williams RR; Kojak C; Rubin A
Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
[TBL] [Abstract][Full Text] [Related]
47. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
Vetter N; Cambronero-Hernandez E; Rohlf J; Simon S; Carides A; Oliveria T; Isaacs R;
Clin Ther; 2002 Nov; 24(11):1770-85. PubMed ID: 12501873
[TBL] [Abstract][Full Text] [Related]
48. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
[TBL] [Abstract][Full Text] [Related]
49. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
50. Ceftaroline fosamil: drug profile and clinical data.
Kanafani ZA
Future Microbiol; 2011 Jan; 6(1):9-18. PubMed ID: 21162631
[TBL] [Abstract][Full Text] [Related]
51. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
[TBL] [Abstract][Full Text] [Related]
53. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
Tanaseanu C; Milutinovic S; Calistru PI; Strausz J; Zolubas M; Chernyak V; Dartois N; Castaing N; Gandjini H; Cooper CA;
BMC Pulm Med; 2009 Sep; 9():44. PubMed ID: 19740418
[TBL] [Abstract][Full Text] [Related]
55. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
Udeani G; Evans J; Cole P; Friedland HD
Hosp Pract (1995); 2014 Aug; 42(3):109-15. PubMed ID: 25255412
[TBL] [Abstract][Full Text] [Related]
56. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Yuan J; Mo B; Ma Z; Lv Y; Cheng SL; Yang Y; Tong Z; Wu R; Sun S; Cao Z; Wu J; Zhu D; Chang L; Zhang Y;
J Microbiol Immunol Infect; 2019 Feb; 52(1):35-44. PubMed ID: 30181096
[TBL] [Abstract][Full Text] [Related]
57. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
Zervos M; Mandell LA; Vrooman PS; Andrews CP; McIvor A; Abdulla RH; de Caprariis PJ; Knirsch CA; Amsden GW; Niederman MS; Lode H
Treat Respir Med; 2004; 3(5):329-36. PubMed ID: 15606222
[TBL] [Abstract][Full Text] [Related]
58. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Tanaseanu C; Bergallo C; Teglia O; Jasovich A; Oliva ME; Dukart G; Dartois N; Cooper CA; Gandjini H; Mallick R; ;
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):329-38. PubMed ID: 18508226
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
60. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corey GR; Wilcox MH; Talbot GH; Thye D; Friedland D; Baculik T;
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv41-51. PubMed ID: 21115454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
